Your browser doesn't support javascript.
loading
Correction: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma.
Wu, Jie; Zheng, Chunlei; Wang, Yizhe; Yang, Zichang; Li, Ce; Fang, Wanxia; Jin, Yue; Hou, Kezuo; Cheng, Yang; Qi, Jianfei; Qu, Xiujuan; Liu, Yunpeng; Che, Xiaofang; Hu, Xuejun.
Affiliation
  • Wu J; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, No.155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Zheng C; Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, Liaoning, China.
  • Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Yang Z; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Li C; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
  • Fang W; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, No.155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Jin Y; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Hou K; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Cheng Y; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
  • Qi J; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Qu X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Liu Y; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
  • Che X; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Hu X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Biomark Res ; 11(1): 51, 2023 May 12.
Article in En | MEDLINE | ID: mdl-37173742
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomark Res Year: 2023 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomark Res Year: 2023 Document type: Article Affiliation country: China